Health TrialsbyHealthPanel

Apremilast and Adalimumab in Psoriatic Arthritis Patients

ConditionsPsoriatic ArthritisUltrasound AssessmentTNF
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorTanta University

About this trial

The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

This study will include 60 adult Psoriatic arthritis patients >18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months.

Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains

Disqualifiers

Patients who received previous biologic agents or Janus kinase inhibitors.

Patients with axial and ocular involvement.

Current or recent serious infection including tuberculosis or hepatitis B/C .

Current or past history of malignancy (within five year).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Adalimumab

    Drug

    PsA patients who will receive Adalimumab with methotrexate therapy for 3 months

  • Apremilast

    Drug

    PsA patients who will receive Apremilast with methotrexate therapy for 3 months

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Group IExperimental treatment 1 intervention
Group B: Group IIExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Disease Activity Index for Psoriatic Arthritis

Assessment of disease activity in psoriatic arthritis patients by Disease Activity Index for Psoriatic Arthritis

Time frame
3 months

Secondary outcomes

1

Health assessment questionnaire disability index

Functional assessment Using health assessment questionnaire disability index

Time frame
3 months
2

Psoriasis Area and Severity Index

Psoriasis Area and Severity Index (PASI) for skin involvement

Time frame
3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tanta University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: